Development of a rapid colorimetric time-kill assay for determining the in vitro activity of ceftazidime and tobramycin in combination against Pseudomonas aeruginosa

Journal of Microbiological Methods

Volumn 61, Issue 2, 2005, Pages 171-179

  Moriarty, Fintan ^a   Elborn, Stuart ^a   Tunney, Michael ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

Antibiotic synergy; Pseudomonas aeruginosa; XTT

Indexed keywords

CEFTAZIDIME; SODIUM CHLORIDE; TETRAZOLIUM; TOBRAMYCIN;

ARTICLE; BACTERIAL GROWTH; BACTERIUM ISOLATE; BACTERIUM ISOLATION; BIOASSAY; COLORIMETRY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYSTIC FIBROSIS; DRUG EFFECT; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; REDUCTION;

PSEUDOMONAS; PSEUDOMONAS AERUGINOSA;

EID: 13844281516     PISSN: 01677012     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mimet.2004.11.010     Document Type: Article

References (30)

1. S.D. Aaron, W. Ferris, D.A. Henry, D.P. Speert, and N.E. MacDonald Multiple combination bactericidal antibiotic testing for patients with cystic fibrosis infected with Burkholderia cepacia Am. J. Respir. Crit. Care Med. 161 2000 1206 1212
2. J.M. Andrews Determination of minimum inhibitory concentrations J. Antimicrob. Chemother. 48 Suppl. 1 2001 5 16
3. P.M. Beringer New approaches to optimizing antimicrobial therapy in patients with cystic fibrosis Curr. Opin. Pulm. Med. 5 1999 371 377
4. D.M. Cappelletty, and M.J. Rybak Comparison of methodologies for synergism testing of drug combinations against resistant strains of Pseudomonas aeruginosa Antimicrob. Agents Chemother. 40 1996 677 683
5. E.G. Chadwick, S.T. Shulman, and R. Yogev Correlation of antibiotic synergy in vitro and in vivo: use of an animal model of neutropenic gram-negative sepsis Infect. Dis. 154 4 1986 670 675
6. W.A. Craig The future-can we learn from the past? Diagn. Microbiol. Infect. Dis. 27 1997 49 53
7. M.A. Dawis, H.D. Isenberg, K.A. France, and S.G. Jenkins In vitro activity of gatifloxacin alone and in combination with cefepime, meropenem, piperacillin and gentamicin against multidrug-resistant organisms J. Antimicrob. Chemother. 51 2003 1203 1211
8. A. De Logu, P. Uda, M.L. Pellerano, M.C. Pusceddu, B. Saddi, and M.L. Schivo Comparison of two rapid colorimetric methods for determining resistance of Mycobacterium tuberculosis to rifampin, isoniazid, and streptomycin in liquid medium Eur. J. Clin. Microbiol. Infect. Dis. 20 2001 33 39
9. A. De Logu, R. Borgna, P. Uda, A. Sanna, M.L. Pellerano, and B. Saddi The 2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide (XTT) assay as rapid colorimetric method for determination of antibiotic susceptibility of clinical Mycobacterium tuberculosis isolates in liquid medium Clin. Lab. 49 2003 357 365
10. A. De Logu, M.L. Pellerano, A. Sanna, M.C. Pusceddu, P. Uda, and B. Saddi Comparison of the susceptibility testing of clinical isolates of Mycobacterium tuberculosis by the XTT colorimetric method and the NCCLS standards method Int. J. Antimicrob. Agents 21 2003 244 250
11. J.A. Dodge, S. Morison, P.A. Lewis, E.C. Coles, D. Geddes, G. Russell, J.M. Littlewood, and M.T. Scott Incidence, population, and survival of cystic fibrosis patients in the UK, 1968-95. UK Cystic Fibrosis Survey Management Committee Arch. Dis. Child. 77 1997 493 496
12. V.M. Figueredo, and H.C. Neu Synergy of ciprofloxacin with fosfomycin in vitro against Pseudomonas isolates from patients with cystic fibrosis J. Antimicrob. Chemother. 22 1 1988 41 50
13. S.P. Hawser, H. Norris, C.J. Jessup, and M.A. Ghannoum Comparison of a 2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-5-[(phenylamino)carbonyl] -2H-tetrazolium hydroxide (XTT) colorimetric method with the standardized National Committee for Clinical Laboratory Standards method of testing clinical yeast isolates for susceptibility to antifungal agents J. Clin. Microbiol. 36 1998 1450 1452
14. S.P. Hawser, C. Jessup, J. Vitullo, and M.A. Ghannoum Utility of 2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-5-[(phenyl-amino)carbonyl] -2H-tetrazolium hydroxide (XTT) and minimum effective concentration assays in the determination of antifungal susceptibility of Aspergillus fumigatus to the lipopeptide class compounds J. Clin. Microbiol. 39 2001 2738 2741
15. C.C. Johnson In vitro testing: correlations between bacterial susceptibility, body fluid levels, and effectiveness of antibacterial therapy V. Lorain Antibiotics in laboratory medicine 1996 The Williams & Wilkins Baltimore, MD 813 834
16. B.J. Lang, S.D. Aaron, W. Ferris, P.C. Hebert, and N.E. MacDonald Multiple combination bactericidal antibiotic testing for patients with cystic fibrosis infected with multiresistant strains of Pseudomonas aeruginosa Am. J. Respir. Crit. Care Med. 162 2000 2241 2245
17. J. Li, J. Turnidge, R. Milne, R.L. Nation, and K. Coulthard In vitro pharmacodynamic properties of colistin and colistin methanesulfonate against Pseudomonas aeruginosa isolates from patients with cystic fibrosis Antimicrob. Agents Chemother. 45 3 2001 781 785
18. J. Meletiadis, J.W. Mouton, J.F. Meis, B.A. Bouman, P.J. Donnelly, and P.E. Verweij Comparison of spectrophotometric and visual readings of NCCLS method and evaluation of a colorimetric method based on reduction of a soluble tetrazolium salt, 2,3-bis [2-methoxy-4-nitro-5-[(sulfenylamino) carbonyl]-2H-tetrazolium-hydroxide], for antifungal susceptibility testing of Aspergillus species J. Clin. Microbiol. 39 2001 4256 4263
19. J. Meletiadis, J.W. Mouton, J.F. Meis, B.A. Bouman, J.P. Donnelly, and P.E. Verweij Colorimetric assay for antifungal susceptibility testing of Aspergillus species J. Clin. Microbiol. 39 2001 3402 3408
20. A.A. Miles, and S.S. Misra The estimation of the bactericidal power of blood J. Hyg. (Camb.) 38 1938 732 749
21. G.A. Pankuch, M.R. Jacobs, and P.C. Appelbaum Study of comparative antipneumococcal activities of penicillin G, RP 59500, erythromycin, sparfloxacin, ciprofloxacin, and vancomycin by using time-kill methodology Antimicrob. Agents Chemother. 38 1994 2065 2072
22. G. Ramage, W.K. VandeWalle, B.L. Wickes, and J.L. Lopez-Ribot Standardized method for in vitro antifungal susceptibility testing of Candida albicans biofilms Antimicrob. Agents Chemother. 45 2001 2475 2479
23. G. Ramage, W.K. VandeWalle, S.P. Bachmann, B.L. Wickes, and J.L. Lopez-Ribot In vitro pharmacodynamic properties of three antifungal agents against preformed Candida albicans biofilms determined by time-kill studies Antimicrob. Agents Chemother. 46 2002 3634 3636
24. A.L. Smith, S.B. Fiel, N. Mayer-Hamblett, B. Ramsey, and J.L. Burns Susceptibility testing of Pseudomonas aeruginosa isolates and clinical response to parenteral antibiotic administration: lack of association in cystic fibrosis Chest 123 2003 1495 1502
25. R. Tellier, M. Krajden, G.A. Grigoriew, and I. Campbell Innovative endpoint determination system for antifungal susceptibility testing of yeasts Antimicrob. Agents Chemother. 36 1992 1619 1625
26. M.M. Tunney, and E.M. Scott Use of breakpoint combination sensitivity testing as a simple and convenient method to evaluate the combined effects of ceftazidime and tobramycin on Pseudomonas aeruginosa and Burkholderia cepacia complex isolates in vitro J. Microbiol. Methods 59 2004 107 114
27. M.M. Tunney, G. Ramage, T.R. Field, T.F. Moriarty, and D.G. Storey Development of a rapid colorimetric assay for antimicrobial susceptibility testing of P. aeruginosa Antimicrob. Agents Chemother. 48 5 2004 1879 1881
28. A. Turner, S.J. Pedler, F. Carswell, G.R. Spencer, and D.C. Speller Serum and sputum concentrations of ceftazidime in patients with cystic fibrosis J. Antimicrob. Chemother. 14 5 1984 521 527
29. P. Vic, S. Ategbo, D. Turck, M.O. Husson, V. Launay, G.A. Loeuille, A. Sardet, A. Deschildre, D. Druon, and C. Arrouet-Lagande Efficacy, tolerance and pharmacokinetics of once daily tobramycin for pseudomonas exacerbation in cystic fibrosis Arch. Dis. Child. 78 1998 536 539
30. K. Weiss, and J.R. Lapointe Routine susceptibility testing of four antibiotic combinations for improvement of laboratory guide to therapy of cystic fibrosis infections caused by Pseudomonas aeruginosa Antimicrob. Agents Chemother. 39 1995 2411 2414